Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma
- First Posted Date
- 2009-06-30
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 281
- Registration Number
- NCT00930514
A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 287
- Registration Number
- NCT00929240
A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B
Phase 4
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2009-06-24
- Last Posted Date
- 2016-03-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 383
- Registration Number
- NCT00927082
ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer
Phase 1
Completed
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2009-06-22
- Last Posted Date
- 2015-08-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT00925769
A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C
Phase 4
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2009-06-17
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6661
- Registration Number
- NCT00922779
A Study of Once Monthly Subcutaneous Mircera in Patients With Chronic Renal Anemia Not on Dialysis
Phase 4
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2009-06-17
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 191
- Registration Number
- NCT00922116
- Locations
- 🇰🇷
Kyungpook National Uni Hospital; Internal Medicine, Daegu, Korea, Republic of
🇰🇷Inje University Busan Paik Hospital; Nephrology, Busan, Korea, Republic of
🇰🇷Chungnam National Uni Hospital; Nephrology, Daejeon, Korea, Republic of
A Study of Mircera in Renal Anemia Among Filipino Chronic Kidney Disease Patients
Phase 4
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2009-06-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 28
- Registration Number
- NCT00922610
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B
Phase 4
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2009-06-17
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 280
- Registration Number
- NCT00922207
- Locations
- 🇨🇳
National Taiwan Uni Hospital; Gastro-Enterology Dept., Taipei, Taiwan
🇨🇳Taipei Veterans General Hospital; Gastroenterology Division, Taipei, Taiwan
🇨🇳Kaohsiung Medical Uni Chung-Ho Memorial Hospital; Dept of Internal Medicine, Kaohsiung, Taiwan
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
- First Posted Date
- 2009-05-28
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 756
- Registration Number
- NCT00909597
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Nonbiologic DMARDs of investigator's choice
- First Posted Date
- 2009-04-30
- Last Posted Date
- 2012-10-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 886
- Registration Number
- NCT00891020
© Copyright 2025. All Rights Reserved by MedPath